

July 26, 2016

The Secretary / Executive Director
BSE Limited
National Stock Exchange of India Ltd.
New York Stock Exchange Inc.

Dear Sir/Madam,

Sub: Outcome of Board Meeting – Unaudited Financial Results for the quarter ended June 30, 2016

Further to our letter dated July 1, 2016, we would like to inform you that the Board of Directors of the Company at their meeting held on July 26, 2016, *inter alia*, have approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2016.

In terms of the above, we are enclosing herewith the following:


1. Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2016 prepared under Indian Accounting Standards (IND-AS).
2. Unaudited Consolidated Financial Results of the Company and its subsidiaries for the quarter ended June 30, 2016 prepared under Indian Accounting Standards (IND-AS).
3. Press Release on Financial Results of the Company for the above period.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are also enclosing the above along with the Limited Review Reports of the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2016.

We have also uploaded the financial results on the website of the Company as also on the website of BSE Ltd. and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively.

This is for your information and records.

With regards,


Sandeep Poddar
Company Secretary

Encl : as above

B S R & Co. LLP

Chartered Accountants

8-2-618/2, Reliance Humsafar.
4th Floor, Road, No. 11,
Banjara Hills
Hyderabad - 500 034. India.

Telephone +91 40 3046 5000
Fax +91 40 3046 5299

Limited Review Report on Quarterly Standalone Financial Results of Dr. Reddy's Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of Dr. Reddy's Laboratories Limited

We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Dr. Reddy's Laboratories Limited ('the Company') for the quarter ended 30 June 2016, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2015 including the reconciliation of profit under Ind AS of the corresponding quarter with profit reported under previous GAAP, as reported in these financial results have been approved by company's Board of Directors but have not been subjected to review.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 26 July 2016. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e., Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 05 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP

Chartered Accountants

Firm's registration number: 101248W/ W-100022



Supreet Sachdev

Partner

Membership Number: 205385

Place: Hyderabad

Date: 26 July 2016

DR. REDDY'S LABORATORIES LIMITED
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

All amounts in Indian Rupees millions, except share data and where otherwise stated

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Income from operations				
	a) Net sales / income from operations (Net of excise duty)	21,285	21,441	25,083	99,218
	b) License fees and service income	41	2,021	46	2,288
	c) Other operating income	89	106	130	571
	Total income from operations (net)	21,415	23,568	25,259	102,077
2	Expenses				
	a) Cost of materials consumed	4,714	4,902	5,012	19,885
	b) Purchase of traded goods	1,594	1,267	1,543	6,104
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,251)	461	(381)	(288)
	d) Employee benefits expense	4,684	4,322	4,066	16,934
	e) Selling expenses	2,521	1,558	2,623	9,275
	f) Depreciation and amortisation	1,725	1,812	1,423	6,495
	g) Other expenditure	6,795	10,735	5,755	29,514
	Total expenses	20,782	25,057	20,041	87,919
3	Profit / (loss) before other income and finance costs (1 - 2)	633	(1,489)	5,218	14,158
4	Other income	3,918	987	1,105	3,249
5	Profit / (loss) before finance costs (3 + 4)	4,551	(502)	6,323	17,407
6	Finance costs	126	147	213	641
7	Profit / (loss) before tax (5 - 6)	4,425	(649)	6,110	16,766
8	Tax expense / (benefit)	334	(262)	1,176	3,023
9	Net profit / (loss) for the period / year (7 - 8)	4,091	(387)	4,934	13,743
10	Other Comprehensive income	(124)	(220)	(14)	(289)
11	Total Comprehensive income (9 + 10)	3,967	(607)	4,920	13,454
12	Paid-up equity share capital (face value Rs. 5/- each)	828	853	853	853
13	Reserves				123,991
14	Earnings per share (in Rupees) per Rs. 5/- share				
	- Basic	24.13	(2.26)	28.95	80.59
	- Diluted	24.07	(2.26)	28.85	80.34
		(Not annualised)	(Not annualised)	(Not annualised)	

See accompanying notes to the financial results

DR. REDDY'S LABORATORIES LIMITED
Segment Information

All amounts in Indian Rupees millions, except share data and where otherwise stated

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	Segment wise revenue and results:				
1	Segment revenue:				
	a) Pharmaceutical Services and Active Ingredients	5,227	6,199	5,778	22,913
	b) Global Generics	17,719	18,854	20,667	84,472
	c) Proprietary Products	-	-	-	1
	Total	22,946	25,053	26,445	107,386
	Less: Inter segment revenue	1,531	1,485	1,186	5,309
	Add: Other unallocable income	-	-	-	-
	Total income from operations	21,415	23,568	25,259	102,077
2	Segment results:				
	Profit / (loss) before tax and interest from each segment				
	a) Pharmaceutical Services and Active Ingredients	(743)	(1,042)	276	(1,324)
	b) Global Generics	3,865	1,667	7,571	23,081
	c) Proprietary Products	(750)	(918)	(723)	(2,975)
	Total	2,372	(293)	7,124	18,782
	Less: (i) Interest	126	147	213	641
	(ii) Other un-allocable expenditure / (income), net	(2,179)	209	801	1,375
	Total profit / (loss) before tax	4,425	(649)	6,110	16,766

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Segmental Capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Notes:

- The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

2 Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter ended 30 June 2015

Particulars	Amounts in Indian Rupees millions
Net profit under previous GAAP	4,758
Impact on account of measuring investments at fair value through profit and loss	196
Recognition of intangible assets not eligible for recognition under Previous GAAP	5
Reversal of goodwill amortised under Previous GAAP	(9)
Difference in measurement of employee share based payments	22
Impact on current and deferred taxes	(37)
Others	(1)
Net profit for the period under Ind AS	4,934

- Other income includes dividend income of Rs. 3,018 million from one of the wholly owned subsidiaries of the Company in Switzerland.
- During the quarter ended 30 June 2016, the Company bought back and extinguished 5,077,504 equity shares for an aggregate purchase price of Rs. 15,694 million. The aggregate face value of the shares bought back was Rs. 25 million.
- Other expenditure for the year ended 31 March 2016 includes provision for doubtful debts of Rs. 3,559 million pertaining to outstanding receivable from Venezuelan subsidiary.




DR. REDDY'S LABORATORIES LIMITED

- 6 The Company received a warning letter, dated 5 November 2015 from the U.S. FDA, regarding deviations with current Good Manufacturing Practices at its API manufacturing facilities in Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as regarding violations at its oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. The Company submitted its response to the warning letter on 7 December 2015. The Company believes that it can resolve the issues raised by the U.S. FDA satisfactorily in a timely manner. The Company takes the matters identified by U.S. FDA in the warning letter seriously and will continue to work diligently to address the observations identified in the warning letter and is concurrently continuing to develop and implement its corrective action plans relating to the warning letter. Further, the Company has provided an update to the U.S. FDA on the progress of remediation in January 2016, March 2016 and May 2016.
- 7 The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 26 July 2016.
- 8 The results for all the periods presented have been subjected to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.

By order of the Board
For Dr. Reddy's Laboratories Limited



G V Prasad

Co-Chairman & Chief Executive Officer

Place: Hyderabad
Date: 26 July 2016



CMS

B S R & Co. LLP

Chartered Accountants

8-2-618/2, Reliance Humsafar,
4th Floor, Road, No. 11,
Banjara Hills
Hyderabad - 500 034. India.

Telephone +91 40 3046 5000
Fax +91 40 3046 5299

Limited Review Report on Quarterly Consolidated Financial Results of Dr. Reddy's Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To
The Board of Directors of Dr. Reddy's Laboratories Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ("the statement") of Dr. Reddy Laboratories Limited ("the company"), its subsidiaries and its jointly controlled entity (the company, its subsidiaries and its jointly controlled entity constitute "the group") for the quarter ended 30 June 2016, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the corresponding quarter ended 30 June 2015 including the reconciliation of profit under Ind AS of the corresponding quarter with profit reported under previous GAAP, as reported in these financial results have been approved by company's Board of Directors but have not been subjected to review.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in the meeting held on 26 July 2016. Our responsibility is to issue a report on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes the results of the following entities:

- 1) Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.
- 2) Aurigene Discovery Technologies Inc.
- 3) Aurigene Discovery Technologies Limited
- 4) beta Institut gemeinnützige GmbH
- 5) betapharm Arzneimittel GmbH
- 6) Cheminor Investments Limited
- 7) Chienna B.V.
- 8) Chirotech Technology Limited
- 9) DRANU LLC
- 10) Dr. Reddy's Bio-Sciences Limited
- 11) Dr. Reddy's Farmaceutica Do Brasil Ltda.
- 12) Dr. Reddy's Laboratories (Australia) Pty. Limited
- 13) Dr. Reddy's Laboratories Canada, Inc.
- 14) Dr. Reddy's Laboratories (EU) Limited



Limited Review Report on Quarterly Consolidated Financial Results of Dr. Reddy's Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (continued)

- 15) Dr. Reddy's Laboratories Inc.
- 16) Dr. Reddy's Laboratories International SA
- 17) Dr. Reddy's Laboratories Japan KK
- 18) Dr. Reddy's Laboratories, LLC
- 19) Dr. Reddy's Laboratories Louisiana LLC
- 20) Dr. Reddy's Laboratories New York, Inc.
- 21) Dr. Reddy's Laboratories (Proprietary) Limited
- 22) Dr. Reddy's Laboratories Romania S.R.L.
- 23) Dr. Reddy's Laboratories SA
- 24) Dr. Reddy's Laboratories SAS
- 25) Dr. Reddy's Laboratories Tennessee, LLC
- 26) Dr. Reddy's Laboratories (UK) Limited
- 27) Dr. Reddy's New Zealand Limited.
- 28) Dr. Reddy's Pharma SEZ Limited
- 29) Dr. Reddy's Singapore PTE Limited
- 30) Dr. Reddy's Srl
- 31) Dr. Reddy's Venezuela, C.A.
- 32) DRL Impex Limited
- 33) Eurobridge Consulting B.V.
- 34) Industrias Quimicas Falcon de Mexico, S.A. de CV
- 35) Idea2Enterprises (India) Pvt. Limited
- 36) Kunshan Rotam Reddy Pharmaceutical Co. Limited
- 37) Lacock Holdings Limited
- 38) OOO Dr. Reddy's Laboratories Limited
- 39) OOO DRS LLC
- 40) OctoPlus B.V. (formerly OctoPlus N.V.)
- 41) OctoPlus Development B.V.
- 42) OctoPlus Sciences B.V.
- 43) OctoPlus PolyActive Sciences B.V.
- 44) OctoPlus Technologies B.V.
- 45) OctoShare B.V.
- 46) Promius Pharma LLC
- 47) Reddy Antilles N.V.
- 48) Reddy Specialities GmbH
- 49) Reddy Cheminor S.A.
- 50) Reddy Holding GmbH
- 51) Reddy Netherlands B.V.
- 52) Reddy Pharma Iberia SA
- 53) Reddy Pharma Italia S.p.A.
- 54) Reddy Pharma SAS
- 55) Kunshan Rotam Reddy Pharmaceutical Co. Limited (accounted in accordance with Ind AS 111)
- 56) DRSS Solar Power Private Limited (accounted in accordance with Ind AS 111)
- 57) DRES Energy Private Limited (accounted in accordance with Ind AS 111)




Limited Review Report on Quarterly Consolidated Financial Results of Dr. Reddy's Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (continued)

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP.

Chartered Accountants

Firm Registration Number: 101248W/W-100022



Supreet Sachdev

Partner

Membership Number: 205385

Date: 26 July 2016

Place: Hyderabad

DR. REDDY'S LABORATORIES LIMITED
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

All amounts in Indian Rupees millions, except share data and where otherwise stated

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2016 (Unaudited)	31.03.2016 (Unaudited)	30.06.2015 (Unaudited)	31.03.2016 (Unaudited)
1	Income from operations				
	a) Net sales / income from operations (Net of excise duty)	31,635	36,735	37,009	151,633
	b) License fees and service income	488	610	363	2,233
	c) Other operating income	102	389	150	975
	Total income from operations (net)	32,225	37,734	37,522	154,841
2	Expenses				
	a) Cost of materials consumed	5,742	5,430	6,330	25,002
	b) Purchase of traded goods	3,282	2,585	3,199	11,743
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,793)	943	(1,050)	(957)
	d) Employee benefits expense	8,050	7,909	7,502	31,174
	e) Selling expenses	3,268	2,685	3,130	11,811
	f) Depreciation and amortisation	2,436	2,767	2,033	9,389
	g) Other expenditure	9,774	13,365	8,541	40,215
	Total expenses	30,759	35,684	29,685	128,377
3	Profit before other income and finance costs (1 - 2)	1,466	2,050	7,837	26,464
4	Other income	670	850	757	2,950
5	Profit before finance costs (3 + 4)	2,136	2,900	8,594	29,414
6	Finance costs	148	170	281	826
7	Profit before tax (5 - 6)	1,988	2,730	8,313	28,588
8	Tax expense	526	1,563	1,888	7,511
9	Net profit for the period / year (7 - 8)	1,462	1,167	6,425	21,077
10	Share of profit of equity accounted investees, net of tax	73	59	49	229
11	Net Profit after taxes and share of profit of associates (9 + 10)	1,535	1,226	6,474	21,306
12	Other comprehensive income	147	(1,408)	779	(370)
13	Total comprehensive income	1,682	(182)	7,253	20,936
14	Paid-up equity share capital (face value Rs. 5/- each)	828	853	853	853
15	Reserves				128,842
16	Earnings per share (in Rupees) per Rs. 5/- share				
	- Basic	9.06	7.19	37.99	124.93
	- Diluted	9.03	7.17	37.86	124.54
		(Not annualised)	(Not annualised)	(Not annualised)	

See accompanying notes to the financial results

DR. REDDY'S LABORATORIES LIMITED
Segment Information

All amounts in Indian Rupees millions, except share data and where otherwise stated

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Segment wise revenue and results:				
	Segment revenue:				
	a) Pharmaceutical Services and Active Ingredients	6,306	7,461	5,691	28,255
	b) Global Generics	26,459	30,740	32,026	127,671
	c) Proprietary Products	623	645	697	2,659
	d) Others	399	381	312	1,703
	Total	33,787	39,227	38,726	160,288
	Less: Inter segment revenue	1,562	1,493	1,204	5,447
	Add: Other unallocable income	-	-	-	-
	Total income from operations	32,225	37,734	37,522	154,841
2	Segment results:				
	Gross profit from each segment				
	a) Pharmaceutical Services and Active Ingredients	1,139	1,195	1,341	4,954
	b) Global Generics	16,339	19,435	20,916	84,427
	c) Proprietary Products	525	533	577	2,217
	d) Others	183	121	121	706
	Total	18,186	21,284	22,955	92,304
	Less: Other un-allocable expenditure / (income), net	16,198	18,554	14,642	63,716
	Total profit before tax	1,988	2,730	8,313	28,588

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Segmental Capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Notes:

- The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.

2 Reconciliation between financial results under Previous GAAP and Ind AS for the quarter ended 30 June 2015

Particulars	Amounts in Indian Rupees millions
Net profit under previous GAAP	6,122
Impact on account of measuring investments at fair value through profit and loss	200
Recognition of intangible assets not eligible for recognition under Previous GAAP	(4)
Reversal of goodwill amortised under Previous GAAP	99
Difference in measurement of employee share based payments	22
Impact on current and deferred taxes	52
Others	(17)
Net profit for the period under Ind AS	6,474

- During the quarter ended 30 June 2016, the Company bought back and extinguished 5,077,504 equity shares for an aggregate purchase price of Rs. 15,694 million. The aggregate face value of the shares bought back was Rs. 25 million.
- Other expenditure for the quarter and year ended 31 March 2016 includes foreign exchange loss of Rs. 3,845 million and Rs. 4,621 million, respectively, on account of currency devaluation and translation of monetary assets and liabilities using SIMADI / DICOM rate pertaining to the Company's Venezuelan subsidiary.

(MSL)



DR. REDDY'S LABORATORIES LIMITED

- 5 The Company received a warning letter, dated 5 November 2015 from the U.S. FDA, regarding deviations with current Good Manufacturing Practices at its API manufacturing facilities in Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as regarding violations at its oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. The Company submitted its response to the warning letter on 7 December 2015. The Company believes that it can resolve the issues raised by the U.S. FDA satisfactorily in a timely manner. The Company takes the matters identified by U.S. FDA in the warning letter seriously and will continue to work diligently to address the observations identified in the warning letter and is concurrently continuing to develop and implement its corrective action plans relating to the warning letter. Further, the Company has provided an update to the U.S. FDA on the progress of remediation in January 2016, March 2016 and May 2016.
- 6 The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 26 July 2016.
- 7 The results for all the periods presented have been subjected to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.

By order of the Board
For Dr. Reddy's Laboratories Limited



G V Prasad
Co-Chairman & Chief Executive Officer

Place: Hyderabad
Date: 26 July 2016

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034, Telangana, India.

CONTACT**INVESTOR RELATIONS**

KEDAR UPADHYE
kedaru@drreddys.com
(Ph: +91-40-66834297)

MEDIA RELATIONS

CALVIN PRINTER
calvinprinter@drreddys.com
(Ph: +91-40- 49002121)

Dr. Reddy's Q1 FY17 Financial Results

Revenues at ₹32.3 billion *(YoY decline of 14%)*

EBITDA at ₹4.0 billion *(12.3% of the revenues)*

PAT at ₹1.3 billion *(3.9% of the revenues)*

Hyderabad, India, July 26, 2016: Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the first quarter ended June 30, 2016 under International Financial Reporting Standards (IFRS).

Q1 FY17: Key Highlights

- Consolidated revenues at ₹32.3 billion, year-on-year decline of 14%
- Gross Profit Margin at 56.2%, declined by ~490 bps over that of last year
- Research & Development (R&D) spend at ₹4.8 billion, year on year increase of 9%. Continued focus on building complex generics and differentiated products pipeline
- Selling, general & administrative (SG&A) expenses at ₹12.3 billion, year on year increase of 12%
- EBITDA at ₹4.0 billion, 12.3% of revenues
- Profit after tax at ₹1.3 billion, 3.9% of revenues

Co-chairman and CEO, GV Prasad said "We have come through a very difficult first quarter, with our top and bottom lines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela. We also faced a number of challenges in the quarter including price erosion and delayed launches as a result of the warning letter, which significantly impacted our earnings. However, we continue to take actions that focus on remediation, strengthening our quality systems and executing on our strong product pipeline. We remain focused on generating long term, sustainable growth."



Dr. Reddy's Laboratories Limited and Subsidiaries

Consolidated Income Statement

Particulars	Q1 FY 17			Q1 FY 16			Growth %
	(\$)	(Rs.)	%	(\$)	(Rs.)	%	
Revenues	479	32,345	100.0	557	37,578	100.0	(14)
Cost of revenues	210	14,167	43.8	217	14,631	38.9	(3)
Gross profit	269	18,178	56.2	340	22,947	61.1	(21)
Operating Expenses							
Selling, general & administrative expenses	182	12,284	38.0	163	10,973	29.2	12
Research and development expenses	71	4,802	14.8	65	4,387	11.7	9
Other operating expense / (income)	(1)	(96)	(0.3)	(2)	(125)	(0.3)	(23)
Results from operating activities	18	1,188	3.7	114	7,712	20.5	(85)
Finance expense / (income), net	(7)	(445)	(1.4)	(3)	(216)	(0.6)	106
Share of (profit) of equity accounted investees, net of income tax	(1)	(74)	(0.2)	(1)	(49)	(0.1)	49
Profit before income tax	25	1,707	5.3	118	7,977	21.2	(79)
Income tax expense	7	444	1.4	25	1,720	4.6	(74)
Profit for the period	19	1,263	3.9	93	6,257	16.6	(80)
Diluted EPS	0.11	7.43		0.54	36.58		(80)

EBITDA Computation

Particulars	Q1 FY 17		Q1 FY 16	
	(\$)	(Rs.)	(\$)	(Rs.)
Profit before tax	25	1,707	118	7,977
Interest (income) / expense net*	(6)	(409)	(5)	(304)
Depreciation	26	1,760	23	1,519
Amortization	14	921	11	749
EBITDA	59	3,979	147	9,941
EBITDA (% to sales)		12.3		26.5

* Includes income from investments




Key Balance Sheet Items

Particulars	As on 30 th June 16		As on 31 st March 16	
	(\$)	(Rs.)	(\$)	(Rs.)
Cash and cash equivalents and Other current Investments	379	25,578	592	39,955
Trade receivables	526	35,499	612	41,306
Inventories	414	27,922	379	25,578
Property, plant and equipment	814	54,951	799	53,961
Goodwill and Other Intangible assets	419	28,284	365	24,644
Loans and borrowings (current & non-current)	557	37,632	496	33,513
Trade payables	188	12,723	182	12,300
Equity	1,690	1,14,112	1,901	1,28,336

Revenue Mix by Segment

Particulars	Q1 FY 17			Q1 FY 16			Growth %
	(\$)	(Rs.)	%	(\$)	(Rs.)	%	
Global Generics	395	26,638	82	459	30,961	82	(14)
North America		15,523			18,516		(16)
Europe*		1,615			1,912		(16)
India		5,223			4,756		10
Emerging Markets [#]		4,277			5,777		(26)
PSAI	70	4,692	15	83	5,614	15	(16)
North America		643			580		11
Europe		1,947			2,350		(17)
India		372			670		(44)
Rest of World		1,730			2,014		(14)
Proprietary Products & Others	15	1,015	3	15	1,003	3	1
Total	479	32,345	100	557	37,578	100	(14)

Handwritten signature



* Europe primarily includes Germany, UK and out licensing sales business

Emerging Markets refers to Russia, other CIS countries, Romania and Rest of the World markets including Venezuela.

Segmental Analysis

Global Generics

Revenues from Global Generics segment are at ₹26.6 billion, year-on-year decline of 14%; decline primarily on account of lower contribution from North America and loss of sales from Venezuela.

- Revenues from **North America** at ₹15.5 billion, year-on-year decline of 16%. Decline primarily on account of increased competition primarily in valgancyclovir and azacitidine, coupled with pricing pressure and moderation in volumes off-take.

As of 30th June, 2016, cumulatively 78 generic filings are pending for approval with the USFDA (76 ANDAs and 2 NDAs under 505(b)(2) route). Of these 76 ANDAs, 50 are Para IVs out of which we believe 18 have 'First to File' status.

- Revenues from **Emerging Markets** at ₹4.3 billion, year-on-year decline of 26%.
 - Revenues from **Russia** at ₹2.3 billion, year-on-year growth of 2%. Moderate growth primarily on account of depreciation of Ruble, in constant currency revenues grew by 23% year-on-year. Sequentially, the revenues have been stable.
 - Revenues from **other CIS countries and Romania** market at ₹0.7 billion, year-on-year decline of 15%.
 - Revenues from **Rest of World (RoW)** territories at ₹1.3 billion, year-on-year decline of 53% primarily on account of no sales in Venezuela. Ex-Venezuela it grew by 19%.
- Revenues from **India** at ₹5.2 billion, year-on-year growth of 10%. NPPA pricing notifications and the WPI based annual price decline impacted growth. Portfolio acquired from UCB well-integrated into our supply chain.
- Revenues from **Europe** at ₹1.6 billion, year-on-year decline of 16%.


Pharmaceutical Services and Active Ingredients (PSAI)

- Revenues from **PSAI** at ₹4.7 billion, year-on-year decline of 16%. Decline primarily on account of lower dispatches in API business on account of the ongoing remediation activities
- During the quarter, 19 DMFs were filed globally of which 2 were in the US. The cumulative number of DMF filings as of 30th June, 2016 was 784.

Proprietary Products (PP)

Subsequent to the approvals received from USFDA for 2 NDAs, the company had launched these two molecules Zembrace™Sym Touch™ (Suma 3 mg) injection and Sernivo™ (betamethasone dipropionate) Spray, 0.05% in the US. The performance of these two molecules is gradually picking up traction.

Handwritten signature



Income Statement Highlights:

- Gross profit margin at 56.2% and declined by ~490 bps over that of previous year primarily led by increased competitive intensity in some of the key products in NAG and relatively lower price realizations. Gross profit margin for Global Generics (GG) and PSAI business segments are at 61.3% and 24.1% respectively.
- SG&A expenses at ₹12.3 billion, year-on-year growth of 12%. This increase is largely due to the ongoing remediation activities, launch related activities for the approved NDAs by PP and certain routine items related to manpower and other spends.
- Research & development expenses at ₹4.8 billion, year-on-year growth of 9%. As a % to sales R&D expenses stood at 14.8% in Q1 FY17 as compared to 11.7% in Q1 FY16. Continued focus on building complex generics and differentiated products pipeline.
- Net Finance income at ₹445 million compared to the net finance income of ₹216 million in Q1FY16. The incremental charge of ₹229 million is on account of:
 - Net foreign exchange gain of ₹36 million in the current quarter vs net foreign exchange loss of ₹88 million in the previous year
 - Increase in profit on sales of investments by ₹54 million.
 - Net increase in interest income of ₹51 million.
- Profit after Tax at ₹1.3 billion
- Diluted earnings per share is at ₹7.4
- Capital expenditure is at ₹3.2 billion.

As per the requirements of Section 133 of the Companies Act, 2013 the company has adopted IND-AS wef 1st April 2016. Consolidated results for the quarter as reported under IND-AS is attached in Annexure 1.

Handwritten signature



Earnings Call Details (06.30 pm IST, July 26, 2016)

The Company will host an earnings call at 06.30 pm IST on July 26, 2016, to discuss the performance and answer any questions from participants. This call will be accessible through an audio dial-in and a web-cast.

Audio conference Participants can dial-in on the numbers below

Primary number:	91 22 3960 0616
Secondary number:	91 22 6746 5826
International Toll Free Number	USA 18667462133
	UK 08081011573
	Singapore 8001012045
	Hong Kong 800964448


Playback of call: 91 22 3065 2322, 91 22 6181 3322

Conference ID: 375#

Web-cast More details will be provided through our website, www.drreddys.com

Transcript of the event will be available at www.drreddys.com. Playback will be available for a few days.

Shoula



About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia and other CIS countries. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

DR. REDDY'S LABORATORIES LIMITED
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2016

All amounts in Indian Rupees millions, except share data and where otherwise stated

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Income from operations				
	a) Net sales / income from operations (Net of excise duty)	31,635	36,735	37,009	151,633
	b) License fees and service income	488	610	363	2,233
	c) Other operating income	102	389	150	975
	Total income from operations (net)	32,225	37,734	37,522	154,841
2	Expenses				
	a) Cost of materials consumed	5,742	5,430	6,330	25,002
	b) Purchase of traded goods	3,282	2,585	3,199	11,743
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,793)	943	(1,050)	(957)
	d) Employee benefits expense	8,050	7,909	7,502	31,174
	e) Selling expenses	3,268	2,685	3,130	11,811
	f) Depreciation and amortisation	2,436	2,767	2,033	9,389
	g) Other expenditure	9,774	13,365	8,541	40,215
	Total expenses	30,759	35,684	29,685	128,377
3	Profit before other income and finance costs (1 - 2)	1,466	2,050	7,837	26,464
4	Other income	670	850	757	2,950
5	Profit before finance costs (3 + 4)	2,136	2,900	8,594	29,414
6	Finance costs	148	170	281	826
7	Profit before tax (5 - 6)	1,988	2,730	8,313	28,588
8	Tax expense	526	1,563	1,888	7,511
9	Net profit for the period / year (7 - 8)	1,462	1,167	6,425	21,077
10	Share of profit of equity accounted investees, net of tax	73	59	49	229
11	Net Profit after taxes and share of profit of associates (9 + 10)	1,535	1,226	6,474	21,306
12	Other comprehensive income	147	(1,408)	779	(370)
13	Total comprehensive income	1,682	(182)	7,253	20,936
14	Paid-up equity share capital (face value Rs. 5/- each)	828	853	853	853
15	Reserves				128,842
16	Earnings per share (in Rupees) per Rs. 5/- share				
	- Basic	9.06	7.19	37.99	124.93
	- Diluted	9.03	7.17	37.86	124.54
		(Not annualised)	(Not annualised)	(Not annualised)	

See accompanying notes to the financial results

DR. REDDY'S LABORATORIES LIMITED
Segment Information

All amounts in Indian Rupees millions, except share data and where otherwise stated

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	Segment wise revenue and results:				
1	Segment revenue:				
	a) Pharmaceutical Services and Active Ingredients	6,306	7,461	5,691	28,255
	b) Global Generics	26,459	30,740	32,026	127,671
	c) Proprietary Products	623	645	697	2,659
	d) Others	399	381	312	1,703
	Total	33,787	39,227	38,726	160,288
	Less: Inter segment revenue	1,562	1,493	1,204	5,447
	Add: Other unallocable income	-	-	-	-
	Total income from operations	32,225	37,734	37,522	154,841
2	Segment results:				
	Gross profit from each segment				
	a) Pharmaceutical Services and Active Ingredients	1,139	1,195	1,341	4,954
	b) Global Generics	16,339	19,435	20,916	84,427
	c) Proprietary Products	525	533	577	2,217
	d) Others	183	121	121	706
	Total	18,186	21,284	22,955	92,304
	Less: Other un-allocable expenditure / (income), net	16,198	18,554	14,642	63,716
	Total profit before tax	1,988	2,730	8,313	28,588

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Segmental Capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Notes:

- The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2016 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- Reconciliation between financial results under Previous GAAP and Ind AS for the quarter ended 30 June 2015**


Particulars	Amounts in Indian Rupees millions
Net profit under previous GAAP	6,122
Impact on account of measuring investments at fair value through profit and loss	200
Recognition of intangible assets not eligible for recognition under Previous GAAP	(4)
Reversal of goodwill amortised under Previous GAAP	99
Difference in measurement of employee share based payments	22
Impact on current and deferred taxes	52
Others	(17)
Net profit for the period under Ind AS	6,474
- During the quarter ended 30 June 2016, the Company bought back and extinguished 5,077,504 equity shares for an aggregate purchase price of Rs. 15,694 million. The aggregate face value of the shares bought back was Rs. 25 million.
- Other expenditure for the quarter and year ended 31 March 2016 includes foreign exchange loss of Rs. 3,845 million and Rs. 4,621 million, respectively, on account of currency devaluation and translation of monetary assets and liabilities using SIMADI / DICOM rate pertaining to the Company's Venezuelan subsidiary.



DR. REDDY'S LABORATORIES LIMITED

- 5 The Company received a warning letter, dated 5 November 2015 from the U.S. FDA, regarding deviations with current Good Manufacturing Practices at its API manufacturing facilities in Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as regarding violations at its oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. The Company submitted its response to the warning letter on 7 December 2015. The Company believes that it can resolve the issues raised by the U.S. FDA satisfactorily in a timely manner. The Company takes the matters identified by U.S. FDA in the warning letter seriously and will continue to work diligently to address the observations identified in the warning letter and is concurrently continuing to develop and implement its corrective action plans relating to the warning letter. Further, the Company has provided an update to the U.S. FDA on the progress of remediation in January 2016, March 2016 and May 2016.
- 6 The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 26 July 2016.
- 7 The results for all the periods presented have been subjected to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.

By order of the Board
For Dr. Reddy's Laboratories Limited



G V Prasad
Co-Chairman & Chief Executive Officer

Place: Hyderabad
Date: 26 July 2016


MSK